⁶⁸Ga-PSMA-11 PET accuracy in recurrent prostate cancer

The role of conventional imaging in the management of prostate cancer (PCa) is confined. In nuclear medicine the use of different radiopharmaceuticals allows to successfully evaluate in vivo PCa, with a safe and non-invasive approach. Scientific data are rapidly growing in this field, especially in the clinical setting of biochemical recurrence. (1) Results from an interesting prospective single-arm clinical trial by Fendler et al. about the assessment of ⁶⁸Ga-PSMA-11 PET accuracy in recurrent PCa were recently published (2).